In two recent studies funded by Lilly, more than 60 percent of the combined 470 participants experienced reduced sleep apnea severity when taking Zepbound as compared to placebo.
Known as glucagon-like peptide-1 (GLP-1) agonists, drugs like Zepbound and Novo Nordisk's Ozempic and Wegovy are becoming known not just for inducing weight loss as they mimic the gut's feeling of fullness, but also for seemingly helping with other conditions.
Already, some of these efforts have borne fruit. In March, the FDA approved Novo's Wegovy weight loss injectable as a treatment for heart disease and stroke risk - a move celebrated by doctors who consider the drugs to be life-changing.
#insurance-coverage #weight-loss-medications #pharmaceutical-companies #off-label-uses #fda-approval
Collection
[
|
...
]